Xinwang W. Duan
Nanchang, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 97 publications
Vunakizumab for Radiographic Axial Spondyloarthritis: A Randomized Clinical Trial.
Journal: JAMA network open
Published: May 08, 2026
Implications of systolic pulmonary artery pressure trajectories in systemic lupus erythematosus-associated pulmonary hypertension: a CSTAR-PAH cohort study.
Journal: Frontiers in immunology
Published: February 28, 2026
Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 Trial.
Journal: Advances in therapy
Published: February 13, 2026
Real-world efficacy and safety of tofacitinib on the progression of skin sclerosis in patients with systemic sclerosis: An analysis of national multicenter data from the Chinese Rheumatism Data Center.
Journal: Journal of the American Academy of Dermatology
Published: December 11, 2025
Exploring clinical subtypes of Chinese patients with psoriatic arthritis based on cluster analysis: a national registry study (CREPAR V).
Journal: Clinical rheumatology
Published: December 09, 2025
LGALS3BP promotes M1 polarization of macrophages and interacts with LGALS3, damaging endothelial function and exacerbating pulmonary arterial hypertension in systemic lupus erythematosus.
Journal: Pathology, research and practice
Published: November 15, 2025
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Efficacy of Subcutaneous Firsekibart in Gout: A Phase Ib/II Clinical Trial.
Journal: International journal of rheumatic diseases
Published: October 17, 2025
Endovascular management of stent graft dislodgement during thoracic endovascular aortic repair: a case report.
Journal: Hong Kong medical journal = Xianggang yi xue za zhi
Published: October 05, 2025
Efficacy and safety of secukinumab in patients with active psoriatic arthritis at Week 16 and up to 52 weeks: Results from a Phase III, randomized, double-blind, placebo-controlled bridging study in China.
Journal: Chinese medical journal
Published: September 07, 2025
Efficacy and Safety of Firsekibart Compared to Etoricoxib for Gout Flares: A Phase 2, Multicenter, Open-label, Active-controlled, Randomized Non-inferiority Trial.
Journal: Rheumatology and therapy
Published: June 30, 2025
Community-based epidemiological study on the prevalence and health status of Spondyloarthritis in residents of Wuyuan County, China, 2023.
Journal: Rheumatology and immunology research
Published: June 13, 2025
Applying Genetic Risk Score to Improve Risk Assessment of New-Onset Lupus Nephritis in Systemic Lupus Erythematosus: A Large-Scale Prospective Cohort Study.
Journal: MedComm
Published: June 09, 2025
Last Updated: 09/26/2026